Staudacher Ingo, Jehle Julian, Staudacher Kathrin, Pledl Hans-Werner, Lemke Dieter, Schweizer Patrick A, Becker Rüdiger, Katus Hugo A, Thomas Dierk
Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Neonatology, University Hospital Heidelberg, Heidelberg, Germany.
PLoS One. 2014 Feb 6;9(2):e88164. doi: 10.1371/journal.pone.0088164. eCollection 2014.
Glioblastoma (GB) is associated with poor patient survival owing to uncontrolled tumor proliferation and resistance to apoptosis. Human ether-a-go-go-related gene K(+) channels (hERG; Kv11.1, KCNH2) are expressed in multiple cancer cells including GB and control cell proliferation and death. We hypothesized that pharmacological targeting of hERG protein would inhibit tumor growth by inducing apoptosis of GB cells. The small molecule hERG ligand doxazosin induced concentration-dependent apoptosis of human LNT-229 (EC50 = 35 µM) and U87MG (EC50 = 29 µM) GB cells, accompanied by cell cycle arrest in the G0/G1 phase. Apoptosis was associated with 64% reduction of hERG protein. HERG suppression via siRNA-mediated knock down mimicked pro-apoptotic effects of doxazosin. Antagonism of doxazosin binding by the non-apoptotic hERG ligand terazosin resulted in rescue of protein expression and in increased survival of GB cells. At the molecular level doxazosin-dependent apoptosis was characterized by activation of pro-apoptotic factors (phospho-erythropoietin-producing human hepatocellular carcinoma receptor tyrosine kinase A2, phospho-p38 mitogen-activated protein kinase, growth arrest and DNA damage inducible gene 153, cleaved caspases 9, 7, and 3), and by inactivation of anti-apoptotic poly-ADP-ribose-polymerase, respectively. In summary, this work identifies doxazosin as small molecule compound that promotes apoptosis and exerts anti-proliferative effects in human GB cells. Suppression of hERG protein is a crucial molecular event in GB cell apoptosis. Doxazosin and future derivatives are proposed as novel options for more effective GB treatment.
胶质母细胞瘤(GB)由于肿瘤增殖失控和对凋亡的抗性而导致患者生存率较低。人类醚 - 去极化相关基因钾通道(hERG;Kv11.1,KCNH2)在包括GB在内的多种癌细胞中表达,并控制细胞增殖和死亡。我们假设对hERG蛋白进行药理学靶向将通过诱导GB细胞凋亡来抑制肿瘤生长。小分子hERG配体多沙唑嗪诱导人LNT - 229(EC50 = 35 μM)和U87MG(EC50 = 29 μM)GB细胞发生浓度依赖性凋亡,并伴有细胞周期停滞在G0/G1期。凋亡与hERG蛋白减少64%相关。通过siRNA介导的敲低抑制HERG模拟了多沙唑嗪的促凋亡作用。非凋亡性hERG配体特拉唑嗪对多沙唑嗪结合的拮抗作用导致蛋白表达恢复和GB细胞存活率增加。在分子水平上,多沙唑嗪依赖性凋亡的特征分别是促凋亡因子(磷酸化促红细胞生成素产生人肝细胞癌受体酪氨酸激酶A2、磷酸化p38丝裂原活化蛋白激酶、生长停滞和DNA损伤诱导基因153、裂解的半胱天冬酶9、7和3)的激活以及抗凋亡聚ADP - 核糖聚合酶的失活。总之,这项工作确定多沙唑嗪为一种小分子化合物,其可促进人GB细胞凋亡并发挥抗增殖作用。hERG蛋白的抑制是GB细胞凋亡中的关键分子事件。多沙唑嗪及其未来衍生物被提议作为更有效治疗GB的新选择。